Review Of WHO Pandemic Flu Preparedness: Data Sequencing And Other Issues 31/03/2016 by Catherine Saez, Intellectual Property Watch 4 Comments Five years after its adoption, a World Health Organization mechanism to help the world be ready for future influenza pandemics is being reviewed. According to several stakeholders invited to share their views, a major challenge is genetic sequence data, which allows digital reproduction of material. Other issues include the relationship of the mechanism to an international convention on access to genetic resources, and the contribution of industry.
GSK Eases IP Rights For Poorest Countries, Considers Patent Pooling For Cancer 31/03/2016 by Catherine Saez, Intellectual Property Watch 2 Comments In light of the United Nations Secretary General’s High-Level Panel on Access to Medicines initiative, the GlaxoSmithKline company today announced steps to further help bring innovative medicines to poor countries.
India, EU Leaders Touch On IPR, Innovation, ICTs, Pharmaceuticals 30/03/2016 by Intellectual Property Watch 1 Comment The leaders of India and the European Council today in Brussels discussed a wide range of topics including intellectual property rights – including geographical indications – innovation, digital issues, and health and pharmaceuticals.
Synthetic Biology: Is Scientific Progress Outrunning Normative Process? Case Of The CBD 30/03/2016 by Catherine Saez, Intellectual Property Watch Leave a Comment A research group announced in March that it has designed the first minimal synthetic bacterial cell. Rapid advances in science seem to be leaving the international normative process lagging behind. Current international instruments are seeking to understand how this new technology will impact their regulatory efforts, while civil society raises high concerns.
WHO: Developing Countries Need Smart IP Systems For Local Medicines Production 25/03/2016 by Catherine Saez, Intellectual Property Watch 2 Comments The World Health Organization has released a report on the role of intellectual property in local production of medicines in developing countries. According to the report, the way countries design their intellectual property system is key in the development of local innovation and production. However, health outcomes will depend on the accessibility and affordability of good-quality essential medicines.
Biotherapeutic Medicines, A New Frontier, Face Regulatory Issues 24/03/2016 by Catherine Saez, Intellectual Property Watch Leave a Comment Biotherapeutic medicines, engineered by living organisms, have opened a promising path to treat major diseases. Near copies of these medicines, called biosimilars, are slowly coming to market, as the originator products become free of intellectual property rights or data protection. However, some regulatory issues are left to be addressed, in particular in developing countries, according to the pharmaceutical industry and the World Health Organization. For patients, information on those products and their affordability are key, said a patient group representative.
Special Report: India Rocked By Report Of Secret Assurance To US Industry On IP 22/03/2016 by Patralekha Chatterjee for Intellectual Property Watch 2 Comments That the Indian government has been under pressure from the United States to change its patent regime is no secret among those who follow the public discourse on intellectual property rights. Now, a new controversy about India’s alleged private assurance to the US-India Business Council (USIBC) and other lobby groups that it would not invoke compulsory licensing for commercial purposes seeks to add fuel to fiery speculation about a shift in India’s policy on IPR.
UN High-Level Panel: Ideas For Change To Global Health And IP System Proliferate 19/03/2016 by William New and Catherine Saez, Intellectual Property Watch 3 Comments Public health advocates, academics, patients, governments and others this week presented further ideas to the United Nations Secretary-General’s High-Level Panel on Access to Medicines on ways to break the longstanding pattern of expensive medical products around the world as a way to pay for research and development.
WTO: Nepal, Tanzania, Ukraine Accept Health Amendment To TRIPS Agreement 18/03/2016 by Intellectual Property Watch 1 Comment The World Trade Organization said today that momentum continues to build among member states to accept a public health amendment to the WTO intellectual property rights agreement, as three more countries adopted it in the past week.
Asian Voices On Access to Medicines: Scrap TRIPS, Voluntary Licences Not Working, FTA Threats 18/03/2016 by Catherine Saez, Intellectual Property Watch 2 Comments Speakers from Asian civil society provided recommendations to the public hearing of the United Nations Secretary General’s High-Level Panel on Access to Medicines held yesterday. They underlined the unaffordability of medicines in their countries, the inefficiency of current mechanisms such as voluntary licensing, and the pressure applied by pharmaceutical companies and the United States and Europe to prevent the use of compulsory licences. One speaker warned against the expert advice given by the World Intellectual Property Organization to least-developed countries, while others pointed to stringent intellectual property measures in free-trade agreements.